CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. The company describes itself as a full-service, non-clinical global drug-development partner. Its work spans research-model technologies, discovery and safety-assessment services (both GLP and non-GLP), and manufacturing support products and services. Clients are supported from target identification through non-clinical development and product release, with three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, split as RMS 21.1%, DSA 59.8%, and Manufacturing 19.1%.

The margin and return figures currently tell a cautionary story. The net margin is -6.0% and ROE is -7.7%. Those negative numbers mean the company is not earning a positive return on its equity base, and its core operations are consuming rather than generating profit on each dollar of revenue. For a services and research-model business, negative returns weaken any argument that scale alone is producing pricing power or cost advantages today. Charles River still has breadth—more than 120 sites across over 20 countries—and a broad scientific portfolio, but the financials show that competitive position has not yet translated into profitable capital generation.

Financial posture

Charles River carries a market capitalization of $13.4 billion and a stock price of $277.41. Its trailing P/E ratio is -57.3, which is a direct consequence of negative trailing earnings; a negative P/E ratio therefore does not function as a conventional valuation multiple and should be read as a profitability warning rather than as a cheap or expensive signal. The same story is captured by the net margin of -6.0% and the ROE of -7.7%.

Beta is 1.41, so the stock has historically moved more sharply than the broad market in both directions. The current RSI is 50.4, essentially neutral, and the 50-day EMA sits at $263.64. Against that backdrop, the $13.4 billion market cap reflects investor expectations for a recovery rather than a snapshot of current earnings power, because the reported bottom line is negative.

Strategic priorities & outlook

The company’s most recent 10-K filing outlines a clear set of near-term priorities. Charles River intends to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, with the bulk of those actions falling in the DSA and RMS segments. It also plans to integrate Discovery Services and Safety Assessment into one overarching DSA organization, supported by a combined sales force and unified leadership approach. A separate priority is to become what management calls the scientific partner of choice by delivering a comprehensive and integrated portfolio designed to accelerate biomedical research and therapeutic innovation. In addition, Charles River expects to continue expanding Biologics Testing Solutions service offerings and facilities in the U.S. and Europe.

Those initiatives are framed by operational scale: $4.0 billion in 2025 revenue, a global footprint of more than 120 sites in over 20 countries, and a January 2026 acquisition of certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, meant to support DSA supply operations and RMS third-party sales.

Macro & geopolitical exposure

Because Charles River sits in the Healthcare / Medical – Diagnostics & Research industry, its business is exposed to several macro and geopolitical forces. Regulatory standards are central: GLP and non-GLP safety-assessment work depends on adherence to rules set by agencies such as the FDA and comparable bodies globally. Any tightening of animal-welfare regulations or restrictions on the importation and use of non-human primates could directly affect research-model sourcing and safety-assessment workflows.

Trade policy also matters. Tariffs, export controls, or customs delays can disrupt the cross-border movement of research models, reagents, and biological samples. Currency moves can shift reported revenue and costs for a company with operations in more than 20 countries. Broader biopharma R&D spending, which is sensitive to capital-market conditions and interest rates, drives demand for outsourced discovery and safety assessment. Finally, labor costs and inflation in specialized scientific talent can pressure margins in a services-heavy business model.

Recent developments

The most recent news flow has been conference-heavy. On September 14 and September 15, 2026, Charles River Laboratories International, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference and at the 2026 Global Healthcare Conference, respectively, with transcripts published by Seeking Alpha. On September 17, BusinessWire reported that Charles River is leveraging expertise in rapid and in vitro methods to reduce cell banking timelines. On September 18, Zacks published a head-to-head comparison, “PGNY vs. CRL: Which Stock Is the Better Value Option?” That headline highlights an analytical debate about relative valuation, though it does not resolve it.

These items show management actively engaged with the investment community and messaging operational efficiency around cell banking, but none of the headlines materially change the financial data outlined above.

Earnings behavior & post-earnings drift

Charles River has delivered a clean beat record over the last eight reported quarters, beating the consensus EPS estimate in all eight quarters for a 100% beat rate. The average earnings surprise across those eight quarters is 9.3%. The average 5-day price move in the trading sessions following those reports is +1.24%, classified as an upward post-earnings drift.

The last four quarters demonstrate that the headline beat record masks meaningful short-term volatility. On August 5, 2026, CRL reported actual EPS of $3.02 versus an estimate of $2.74, a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the following five days. On May 7, 2026, actual EPS of $2.06 beat the $1.96 estimate by 5.1%, yet the stock fell 2.23% the next day and 12.42% over the subsequent five sessions. On February 18, 2026, actual EPS of $2.39 beat the $2.33 estimate by 2.6%, producing a 3.95% next-day gain and a 6.05% five-day gain. On November 5, 2025, actual EPS of $2.43 beat the $2.32 estimate by 4.7%, with the stock moving up 1.9% the next day and 2.27% over the next five days.

Going forward, the next scheduled earnings date is November 4, 2026, before the open, with a consensus EPS estimate of $2.96. The historical record suggests the company has habitually exceeded the official estimate, but the market’s reaction afterward has been mixed and at times sharply negative despite the beat.

For a deeper dive into how institutional models are weighing the upcoming November 4, 2026 earnings report, the site-consolidation plan, and the path back to positive ROE, readers should consult the full institutional verdict rather than relying solely on headline data.